This trial is evaluating whether Etoposide will improve 1 primary outcome and 2 secondary outcomes in patients with Cancer. Measurement will happen over the course of time from the date of randomization to the date of disease relapse or death (i.e. up to 1 year).
This trial requires 64 total participants across 2 different treatment groups
This trial involves 2 different treatments. Etoposide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Although cancer is technically technically cureable, only a small minority of patients will have their cancers or life-threatening disease cured. Current chemotherapeutic treatment approaches cannot cure or prevent cancer. Although cures have sometimes been claimed, there are no cures for cancer.
The word cancer is an archaic term from the Latin word kome (from κόμη/κωμες, "kome/kōmēs", "a swelling or lump"). The word cancer appears for the first time in Arabic-speaking medical literature at the beginning of the 12th century, in 'al-Tasrif by Yaqut al-Hamawi (d. 1186). When a tumor is encountered in the medical literature, it is called cancer. A typical tumor is a lump or swelling in one or more parts of the body.\nhttps://www.medxipedia.com/doi/full/10.
The use of multiple conventional cancer treatments is common in older people and is associated with increased risk of death. Alternative treatments may be useful in older people with cancer in terms of improvement in quality of life, functional status, and anticancer treatment side-effects. However, clinical research is limited and requires further investigation.
The cause of cancer may have multiple causes, and research efforts to discover the causes may be overworked. It is necessary to find a new way to think about the causation of cancer, and to reduce or eliminate the various causes from the epidemiology of cancer.
2,850,000 to 6,100,000 new diagnoses of cancer will be made a year in the United States. The American Cancer Society estimates that 1 in 50 men, and 1 in 80 women, in the United States will be diagnosed with some form of cancer by the year 2037.
Use of etoposide with other therapies was most common in patients with myelodysplastic syndrome (MDS), aplastic anaemia, chronic myelomonocytic leukaemia and advanced non-Hodgkin's lymphoma. Patients with AL amyloidosis and AL K-ras mutations were most likely to be treated with etoposide and a myelosuppressive agent, whereas patients with AL with the FH5LTR mutation were more likely to receive etoposide alone.
These data seem to imply that the primary cause of cancer is an aneuploidy, a chromosomal aberration involving the entire genome of cells. It is postulated that such changes result in a loss of normal gene control. This change, rather than a mutation of an inherited sequence such as DNA or a gene, is the cause of cancer. The implication is that DNA damage caused by the aneuploidy is the cause of cancer. One possible mechanism of aneuploidy-induced chromosomal instability is that cancer cells have an excess of DNA damage-repair proteins compared to healthy noncancer cells.
The 5-year survival rate for cancer is 40 percent. Survival time depends enormously upon the cancer type diagnosed and its grade, or stage. The more recent 5-year survival rate for lung cancer in women has been consistently rising since a surge in the 1970-1980s. 5-year survival on average has been increasing. Lung adenocarcinoma (which is the most common type of lung cancer in females) has been shown to be the tumor which has the highest 5-year survival in women (66 percent in 2000 compared with 50 percent in 1955) and in men (64 percent in 2000 compared with 55 percent in 1955).
The severity of a cancers depends on two major factors: the type of cancer and the age of the person. For example, even a person who has only been diagnosed with breast cancer is at risk, as the brain remains responsive to hormones even after all cancer has been surgically removed from the body. Likewise, the younger a person is, the more severely his or her cancer will progress. People whose cancer hasn't penetrated into a major organ will be able to live a relatively normal life and will not necessarily be as likely to die of the cancer or any complications connected to the onset of the cancer.
Data from a recent study provide strong support for the notion that etoposide induces a complex cascade of protein degradation events that culminate in the proteasome-dependent degradation of multiple targets.
The evidence in the literature does not support the assumption that a large part of the population would be willing or able to join the clinical trials of an experimental chemotherapy regimen given to only the 20% of patients who would be eligible for the trial. In our study population, patients with more experience and in whom the prognosis is not so dire, were less enthusiastic about trials.